comparemela.com

Latest Breaking News On - மருந்து ப்ரொட்யூஸர்ஸ் - Page 1 : comparemela.com

Focused COVID-19 Media Monitoring, Nepal (May 20, 2021) - Nepal

Focused COVID-19 Media Monitoring, Nepal (May 20, 2021) Format EMERGING THEME(S) Epidemiology and Disease Control Division says new COVID-19 variant B.1.617.2 is 50 per cent more infectious than previous variants; it is aggressive and deadly, warns Director of Sukraraj Tropical and Infectious Disease Hospital Nepal reports 8,064 new COVID-19 infections, 246 deaths on May 19; infection in Nepal reported as being highest in age group of 20-39 years, those in 30-39 group most affected Government finally starts procurement process of COVID-19 vaccines from India and Russia, has not initiated it with China as Department of Drug Administration does not have address of Chinese company to send the correspondence to; Serum Institute of India will start exporting its COVID-19 vaccine only by the yearend

OPPI warns against vaccine patent waiver

OPPI warns against vaccine patent waiver Top Searches OPPI warns against vaccine patent waiver TNN / Updated: May 12, 2021, 06:19 IST FacebookTwitterLinkedinEMail Representative image MUMBAI: Waiving of intellectual property (IP) rights will neither lead to higher production of vaccines or their increased deployment to fight Covid, since that is not the barrier to ensure availability of vaccines in India, according to the Organisation of Pharmaceutical Producers (OPPI), a body representing pharma MNCs. It warned that a waiver of patents could impact patient safety by opening doors for counterfeit vaccines to enter the supply chain. The statement follows a drastic turnaround of the US recently supporting a waiver of IP on Covid vaccines. India and South Africa are engaged jointly at the World Trade Organization for a patient waiver submitted in October last year for all Covid medical tools. Recently, faced with crucial vaccines shortages and key Covid drugs, there has been dem

IP waiver proposal may open door to counterfeits: OPPI - The Hindu BusinessLine

As a global proposal from India and South Africa to waive intellectual property (IP) on Covid-19-linked health technologies garners support, the Organisation of Pharmaceutical Producers of India (OPPI) has countered that such a move “will neither lead to increased production of vaccines nor increased deployment”. Instead, they caution, it could open the door for counterfeit vaccines. OPPI’s response comes days after the US put its might behind the IP waiver for vaccines during the pandemic period, a move that is expected to swing the support of other countries that may have earlier opposed the proposal at the WTO.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.